Bone graft substitute receives CE mark approval: 3 notes

Written by Shayna Korol | February 05, 2019 | Print  |

Sirakoss received CE mark approval for its Osteo3, a new nano-synthetic bone graft substitute designed for use in bone fracture repair.

Three things to know:

1. Based on Sirakoss' proprietary nano-porous technology, Osteo3 consists of an inorganic matrix designed to be completely reabsorbed into the bone.

2. Osteo3 is intended for use as a bone graft material for filling skeletal system voids or gaps. It can be used alone or in combination with autograft or allograft.

3. Sirakoss is a nano-synthetic bone graft substitute developer.

More articles on biologics:
CollPlant names new board chairman: 4 insights
Ortho RTi releases results of 2 regenerative medicine studies
California neuroscience institute joins regenerative medicine clinical trial: 5 notes

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months